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The ultimate goal of cancer therapy is to destroy cancer cells selectively without 
affecting the normal tissues of the patients. Unfortunately, most of the currently available 
anticancer agents (as well as radiation therapy) target DNA or the enzymes involved in 
DNA replication so that they can exploit the highly proliferative nature of cancer cells. 
As such they do not possess any selectivity towards cancer cells and equally destroy all 
rapidly dividing cells including normal cells in vital tissues such as lympho-hematopoetic 
tissues, gonad, hair follicles and the lining epithelium of gastrointestinal tract and mouth. 
This limits the doses of these anticancer agents applied to cancer patients causing 
incomplete killing of cancer cells. As a result, cancer cells eventually acquire drug-
resistance on prolonged treatment. Recurrence of cancer is also an inevitable 
consequence of this incomplete killing.  
 
A lot of developmental researches across the globe are devoted to break free from 
these limitations with alternative approaches towards cancer therapy. Novel therapies are 
constantly being discovered, developed and trialed. Among them, antiangiogenic therapy 
and targeted cancer therapy are two important strategies for selective cancer eradication.    
 
The principle behind antiangiogenic therapy is elegantly simple. Angiogenesis, 
the process of sprouting new blood vessels from pre-existing ones, is a necessary step for 
the growth of tumors. During initial stages of tumor formation, the dividing cancer cells 
utilize the pre-existing circulation network to acquire food, oxygen and other important 
stuffs. But as the tumor grows, demand of food and oxygen outweighs their supply and 
the need for newer supply lines becomes inevitable. The tumor cells then start secreting 
various enzymes and growth signals, which direct nearer blood vessels to form sub 
vessels directed toward the tumor. If this formation of newer blood vessels is inhibited, 
the growth of tumors will be repressed due to insufficient supply of food and oxygen.  
 
The main targets of antiangiogenic therapy are the growth signals secreted by 
tumor cells. However, the pathways having direct or indirect effect on angiogenesis may 
also provide useful targets. Through modulation of these pathways, angiogenesis may be 
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inhibited. In the first chapter of the present thesis, inhibitors of such a pathway, namely 
N-end rule pathway, are developed and evaluated for antiangiogenic effects in vitro. 
 
Targeted cancer therapy, on the other hand, aim specific molecular pathways or 
cellular targets, which differentiate cancer cells from normal cells. As for example, 
certain receptors are over-expressed in various cancers, whereas the levels of expression 
of those receptors in normal cells and tissues are basal. So, if an anticancer agent is 
developed which can target those receptors, cancer cells will be selectively destroyed 
leaving the normal tissues unaffected. The development and evaluation of such a 
receptor-targeted anticancer agent is described in the second chapter of the present thesis.             
 
Chapter 1: 
 
In This chapter, the development of synthetic bivalent inhibitors of N-end rule 
ubiquitin pathway and their bio-evaluation as inhibitors of angiogenesis and endothelial 
cell proliferation is described. N-end rule pathway is a subset of ubiquitin-dependent 
proteolysis pathway where the proteolytic fate of proteins is determined by the identity of 
their N-terminal residues. The proteins with stabilizing N-terminal residues (e.g. Met, 
Val) are not degraded in this pathway and are stable. On the other hand, proteins with 
destabilizing N-terminal residues (e.g. Arg, Phe, Lys, Leu) are rapidly degraded and are 
pretty much unstable. The proteins bearing basic N-terminal residues (e.g. Arg, Lys, His) 
are type 1 substrates and the proteins bearing large hydrophobic N-terminal residues (e.g. 
Phe, Leu, Ile) are type 2 substrates of the N-end rule pathway. The degradation pathway 
consists of two successive steps: (i) covalent attachment of multiple ubiquitin molecules 
to the target protein (ubiquitination) through recognition by N-recognins and (ii) 
degradation of the ubiquitin-tagged protein by the 26S proteasome. N-recognins are the 
ubiquitin ligases involved in N-end rule pathway that bind to the target proteins and 
attach polyubiquitin chains to them. So, for selective inhibition of the N-end rule pathway 
of protein degradation, these N-recognins become a lucrative target.    
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The reason behind developing the inhibitors of N-end rule pathway stemmed from 
the profuse physiological significance of the N-end rule pathway in various diseases and 
pathological disorders. N-end rule pathway is highly involved in muscle wasting caused 
by enhanced breakdown in skeletal muscles in patients with acute diabetes. It also seems 
to be activated in cancer cachexia, sepsis and hyperthyroidism. But the most important 
significance of N-end rule pathway discovered till date is its role in cardiovascular 
development through modulation of the degradation of regulatory RGS proteins. Some of 
these RGS proteins (especially RGS4 and RGS5) act as negative regulator of 
angiogenesis also. Since the degradation of RGS4 and RGS5 is regulated by N-end rule 
pathway, inhibition of this pathway should lead to inhibition of angiogenesis. As 
angiogenesis is a necessary step in cancer proliferation, these inhibitors may be a 
promising lead towards antiangiogenic cancer therapy.  
 
The structural characterization of N-recognins reveals the presence of at least two 
spatially proximal binding sites: type 1 site binds to basic N-terminal residues (e.g. Arg, 
Lys, His) and the type 2 site binds to bulky hydrophobic N-terminal residues (e.g. Phe, 
Leu, Trp, Ile). Dipeptides bearing either type 1 or type 2 N-terminal residues (e.g. Arg-
Ala, Phe-Ala) have been shown to inhibit the N-end rule pathway. However, they only 
inhibited the degradation of corresponding substrates (i.e. dipeptide with type 1 residue 
inhibited the degradation of type 1 substrates and vice versa). The effective inhibitory 
concentration was very high also. Now, if a molecule possesses both these types of N-
terminal residues in such a way that they can simultaneously bind to these spatially 
proximal binding sites, it can act as a much more effective hetero-bivalent inhibitor of N-
end rule pathway. The synthesis and bio-evaluation of such a hetero-bivalent inhibitor, 
RF-C11, is described in the present study.  
 
Synthesis of RF-C11 was achieved by conjugating Arg and Phe, as heterovalent 
ligands, to the ε- and α- amino groups of a core lysine moiety through hydrocarbon 
linkers (C=11). Two homovalent inhibitors, RR-C11 (bearing Arg at its both termini) and 
FF-C11 (bearing Phe at its both termini), were also synthesized to examine the effects of 
homovalent interactions as compared to heterovalent interaction. A structural control, 
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GV-C11 (bearing Gly and Val at its termini), was synthesized as a control to explore the 
non-selective interaction.  
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Figure 1: Structures of the synthesized bivalent inhibitors of N-end rule pathway. 
 
All the synthesized bivalent inhibitors were examined for their efficiency in 
inhibiting the N-end rule pathway mediated protein degradation in vitro and in vivo in the 
laboratory of Dr. Yong Tae Kwon in University of Pittsburgh, USA. The heterovalent 
inhibitor RF-C11 was the most effective in inhibiting the degradation of both type 1 and 
type 2 N-end rule substrates. RR-C11 inhibited the degradation of type 1 substrates only, 
though at higher concentrations in comparison to RF-C11. Similarly, FF-C11, at higher 
concentrations, inhibited the degradation of type 2 substrates only. Even co-treatment of 
RR-C11 and FF-C11 was not as much effective as RF-C11. RF-C11 was much more 
effective than dipeptides or mixture of dipetides also. RF-C11 also inhibited the in vitro 
ubiquitination and degradation of RGS4, a substrate of mammalian N-end rule pathway, 
whereas RR-C11 was effective to some extent; FF-C11 or GV-C11 had no such effect. 
RF-C11 even inhibited the in vivo degradation of RGS4, the first of its kind in doing so. 
This higher efficacy of RF-C11 is probably the result of the simultaneous and co-
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operative binding of the heterovalent ligands Arg and Phe to the binding sites of N-
recognins.  
 
The synthesized inhibitors were also tested for antiangiogenic and 
antiproliferative properties in Human Umbilical Vein Endothelial Cells (HUVEC) to 
discern any potential role of N-end rule pathway in angiogenesis. Human umbilical vein 
endothelial cells (HUVEC) have long been used as an in vitro model to perform 
angiogenesis related studies. When cultured normally on collagen or gelatin coated 
surface, HUVEC form typical confluent monolayers, but if cultured on matrigel or fibrin 
gels in presence of suitable growth factors, they tend to align themselves through cell-cell 
interactions and start to form capillary network on longer keeping. However, when 
HUVEC were cultured on fibrin gel in presence of RF-C11, the aligning tendency 
decreased to a significant extent. RR-C11 also inhibited the alignment to some extent, but 
FF-C11 or GV-C11 completely failed to induce an inhibitory effect. Not surprisingly, this 
result is in accord with the efficiency of the bivalent inhibitors in stabilizing RGS4.  
 
Besides inhibiting the aligning tendency of HUVEC, RF-C11 also inhibits the 
endothelial cell proliferation as manifested by the BrdU incorporation assay. During 
DNA replication, BrdU can be incorporated into the newly synthesized DNA of the 
dividing cells. So incorporation of BrdU may be considered as a measure of cell 
proliferation. RF-C11 significantly decreases the percentage of BrdU uptake (p<0.01) 
compared to other homovalent inhibitors. Interestingly, GV-C11 also shows some 
inhibition. The reason behind this apparent anomaly became clear in the trypan blue 
exclusion assay. When endothelial cells treated with the bivalent inhibitors were 
subjected to trypan blue exclusion assay, it had been found that GV-C11 actually killed 
the cells non-specifically as evident from the significantly lower cell viability (p<0.01). 
The viabilities in presence of all the other inhibitors were more or less same. So, the anti-
proliferative effect of RF-C11 towards endothelial cells is not toxicity-related; rather 
some other mechanism might be involved.  
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Therefore, this study demonstrates the development of a novel synthetic 
heterovalent inhibitor of N-end rule pathway, which possesses significant antiangiogenic 
and antiproliferative property towards endothelial cells. Since, angiogenesis is a hallmark 
phenomenon in the process of cancer proliferation, fine tuning the structural aspect of this 
kind of inhibitors is expected to develop a new class of antiangiogenic drug for possible 
treatment of cancer.   
 
Chapter 2: 
 
The second chapter of the present thesis describes the development and biological 
evaluation of a novel series of cationic haloperidol derivatives consisting twin chain lipid 
moieties as sigma receptor-targeted anticancer therapeutics. Sigma receptors are a family 
of membrane bound proteins that exist mainly in the central nervous system and various 
peripheral tissues at basal levels. However, a diverse set of human and rodent tumors 
including neuroblastoma, glioma, melanoma and carcinomas of breast, prostate and lung 
have also been shown to over-express sigma receptors. Structurally diverse sigma ligands 
have been shown to exhibit high affinity to these sigma receptor-expressing cells, 
suggesting the prospect of using them for the diagnostic imaging as well as therapeutic 
agents. Haloperidol is such a sigma ligand that has been shown to inhibit cell 
proliferation and induce cell death with signs of apoptosis in moderate concentrations. 
However, in spite of the fact that haloperidol shows significant anti-proliferative activity 
towards cancer cells, its full potential has never been realized through proper chemical 
modifications. Interestingly, a recent study utilized a chemically modified haloperidol to 
target breast cancer cells over-expressing sigma receptors. This finding indicated that the 
targeting ability of haloperidol remain potentially unchanged when conjugated to other 
moieties using slight chemical modifications. So, we hypothesized that by conjugating a 
suitable chemical moiety to haloperidol, the anti-proliferative activity may be enhanced 
without hampering the targeting ability. 
 
     Towards this end, a series of cationic haloperidol derivatives consisting twin 
chain lipid moieties (namely HP-C4, HP-C8, HP-C12 and HP-C16) were synthesized. In 
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all those derivatives the tertiary –OH group of haloperidol was chemically modified by 
esterification with β-alanine. The amine group of this β-alanine moiety was further 
attached to the cationic twin chain lipids via a glycine moiety (the nitrogen atom in 
glycine being the polar head of the cationic lipids) in between. So the actual spacer 
between haloperidol and cationic lipid moiety became 6-atom long. A cationic lipid 
control molecule was also synthesized for further studies where the haloperidol moiety 
along with the 6-atom spacer was replaced by an n-propyl group. 
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Figure 2: General structure of cationic haloperidol derivatives. 
 
At first, the synthesized derivatives were screened for their anti-proliferative 
effects on two sigma receptor over-expressing breast cancer cell lines (MCF-7 and MDA-
MB-231) using MTT assay to identify the derivative with C8 twin chain (HP-C8) as the 
most effective one. Therefore it was used in all further experiments. The cytotoxicity of 
HP-C8 in four different cancer cell lines (MCF-7, MDA-MB-231, ZR-75-1 and B16F10) 
and two normal cell lines (COS-1 and HEK-293) were further evaluated along with 
parent drug molecule haloperidol and cationic lipid control molecule. HP-C8 clearly 
showed significantly higher toxicity compared to either haloperidol or C8 control 
(p<0.001) in all the four cancer cell lines tested over all the tested concentrations. In 
normal cells, however, HP-C8 had more or less similar toxicity profile compared to the 
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C8 control molecule at concentrations 5µM or less. This indicates that the C8 control 
molecule has no specific toxicity towards the cancer cells; rather it has non-specific effect 
to both cancer and non-cancer cells, whereas HP-C8 has specific toxic effect towards 
cancer cells at viable concentrations of 5µM or less. Flow cytometric studies using 
Annexin V were also performed in different cell lines to show that the apoptosis inducing 
efficacy of the derivative was much higher than haloperidol itself. 
 
To examine whether this specific toxic effect of HP-C8 is linked to sigma 
receptors, siRNA mediated down-regulation studies (in MCF-7 and COS-1 cells) were 
performed. It was found that down-regulation of sigma receptor in MCF-7 cells increased 
the cell viability in presence of HP-C8. Naturally, siRNA mediated down-regulation of 
sigma receptor expression in MCF-7 cells caused lesser amount of sigma receptor 
available for HP-C8 binding ultimately leading to the increase in cell viability. No such 
increase was observed in COS-1 cells where sigma receptor is expressed at a basal level 
and further down-regulation did not probably make a noticeable difference. Therefore it 
can be primarily concluded that the toxicity of HP-C8 could significantly be sigma 
receptor mediated, although this mode of toxicity may not be the only exclusive 
mechanism for its induced toxicity. 
 
The efficacy of the derivative towards in vivo tumor growth inhibition was also 
tested in B16F10 melanoma mouse model. HP-C8 showed significant inhibition of tumor 
growth (p<0.05) compared to the parent compound haloperidol. Towards understanding 
the mechanism of HP-C8’s antitumor activity, a mechanistic study was performed. 
Western blots of the lysate obtained from melanoma cells treated with haloperidol or HP-
C8 showed that HP-C8 decreased the expression of anti-apoptotic Bcl-2 and increased the 
expression of pro-apoptotic Bax and activated caspase 3 in comparison to haloperidol. 
This confirmed the onset of apoptosis as a result of HP-C8 treatment. Similar 
experiments with HUVEC showed inhibition of Akt and pAkt expression and an 
increased expression of caspase 3 in HP-C8 treated cells, haloperidol had no such effect. 
Since Akt and pAkt are responsible for the activation of endothelial nitric oxide synthase 
(eNOS), their absence leads to impaired angiogenesis which may be the other important 
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factor other than apoptosis in the HP-C8 mediated growth inhibition in highly aggressive 
melanoma tumors. Furthermore, increased expression of activated caspase 3 indicates 
apoptosis induction in tumor vasculature which also leads to inhibition of tumor growth.  
 
Therefore this study demonstrates the development of a novel sigma-receptor 
targeted anticancer agent from readily available cheap generic drug haloperidol. This 
derivative possesses significant antitumor effect which may be a combined result of 
apoptosis induction in tumor tissues and impaired tumor angiogenesis. Therefore, it may 
provide a promising lead towards developing new anticancer therapeutics.        
 
 
 
    
 
 
 
 
 
